earnings
confidence high
sentiment neutral
materiality 0.75
Tivic Health Q1 revenue drops 79% to $70K; pursues Entolimod and ncVNS pipeline
Valion Bio, Inc.
2025-Q1 EPS reported
-$2.52
revenue$70,000
- Revenue fell 79% YoY to $70K; net loss unchanged at $1.5M. Cash $669K vs $2.0M at year-end.
- Licensed Phase III TLR5 agonist Entolimod for ARS; began GMP manufacturing validation for BLA.
- Briefed White House and FDA on defense applications; secured $25M equity line and $8.4M purchase agreement.
- Expanded ncVNS optimization study; regained Nasdaq compliance via 1-for-17 reverse split in March.
- Gross margin improved to 72% (vs 50% a year ago) but operating expenses flat at $1.6M.